Melbourne-based Telix Pharmaceuticals (ASX:TLX), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or 'molecularly-targeted radiation' (MTR), has announced the extension of its research collaboration with the Institute for Radiation Sciences (IRS), Osaka University and the Department of Nuclear Medicine and Tracer Kinetics at Osaka University Graduate School of Medicine.
The company said the collaboration is partially funded by a grant from the Japan Science and Technology Agency (JST) through their Open Innovation Platform with Enterprises, Research Institute and Academia (OPERA) program.
The matched funding totals US$260,000 and is managed through Telix’s wholly owned subsidiary, Telix Pharmaceuticals Japan KK.
According to Professor Jun Hatazawa, “The first season of this successful collaborative research with Telix was a particular highlight for us and we expect to reinforce early promising data in the 2nd season, for the step up to clinical stage activity.”
Telix Pharmaceuticals Japan President, Dr Shintaro Nishimura, said, “This collaboration and the promising results obtained to date have established a solid foundation for Telix’s interest in alpha-therapy. With the collaboration of Prof. Hatazawa and his colleagues at Osaka University, and the ongoing support from JST through the OPERA program, are making good progress toward clinical evaluation of this technology in Japan.”
The company said key outcomes from the collaboration's first year include the observation of promising efficacy of an 211At variant of TLX101, with the publication of the results planned. It said a new 211At synthesis of -TLX102 was developed.